Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Rheumatoid Arthritis

Clinical and regulatory intelligence for Rheumatoid Arthritis with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
7
Catalysts
0
Assets
2

Relevant assets

Evaluation →
Leflunomide →

Relevant companies

Barr Pharmaceuticals →

Recent signals(7)

ClinicalAugust 4, 2026

Study on Fecal Microbiota Transplantation for Refractory Rheumatoid Arthritis Initiated

A 24-week randomized, double-blind study is underway to assess the efficacy and safety of oral fecal microbiota transplantation in patients with refractory rheumatoid arthritis.

ClinicalJuly 30, 2026

Study on Gluten-Free vs Mediterranean Diets in Rheumatoid Arthritis Launched

A new clinical trial is evaluating the effects of gluten-free and Mediterranean diets on rheumatoid arthritis patients over 12 weeks.

ClinicalJuly 28, 2026

Study on ACPA and RA Origins Aims to Uncover Lung Inflammation Links

A study is underway to investigate the relationship between anti-citrullinated protein antibodies and lung inflammation in rheumatoid arthritis patients.

RegulatoryJuly 22, 2026

FDA Accepts Supplement Application for Leflunomide by Barr

The FDA has accepted a supplemental application for Leflunomide submitted by Barr.

ClinicalJuly 13, 2026

Study on Lung Disease Prevalence in Early Rheumatoid Arthritis Patients

The study aims to characterize lung disease prevalence in early rheumatoid arthritis patients and identify novel biomarkers.

ClinicalJuly 5, 2026

Evaluation of OPTIBIO Tool for Medication Reduction in Rheumatoid Arthritis

A clinical trial is assessing the OPTIBIO predictive tool to guide medication reduction in RA patients in remission.

ClinicalJune 19, 2026

Study on Cardiac Rehabilitation in Hypertensive Rheumatoid Arthritis Patients Initiated

A clinical trial is underway to assess the effects of a 6-week cardiac rehabilitation program in hypertensive patients with controlled rheumatoid arthritis.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Immunology →
Rheumatoid Arthritis →
Rheumatology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.